한빛사 논문
Baolin Tang1,2,3, Jong Bok Lee4,5,6, Siqi Cheng7, Tianzhong Pan1,2,3, Wen Yao1, Dongyao Wang1, Meijuan Tu1, Zhiqiang Xiang8,9, Xiandeng Chu10, Liangquan Geng1, Ping Qiang1, Pingping Teng8,9, Guangyu Sun1, Huilan Liu1,2,3, Jian Wang1, Aaron D. Schimmer11, Liming Yang8,9, Zimin Sun1,2,3, Li Zhang4,5,6, Xiaoyu Zhu1,2,3
1Department of Hematology, The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine, University of Science andTechnology of China, Hefei, China 2Blood and Cell Therapy Institute, Division of Life Sciences and Medicine,University of Science and Technology of China, Hefei, China 3Anhui Provincial Key Laboratory of Blood Research and Applications,Hefei, China 4Transplantation Department, Toronto General Hospital ResearchInstitute, University Health Network, Toronto, Ontario, Canada 5Department of Laboratory Medicine and Pathobiology, University ofToronto, Toronto, Ontario, Canada 6Department of Immunology, University of Toronto, Toronto, Ontario,Canada 7Department of Hematology, Huaibei People's Hospital, Huaibei, China 8R&D Center, WYZE Biotech Co., Ltd, Hangzhou, China 9Cell Manufacturing Department, Ruichuang Biotechnology Co., Ltd,Shaoxing, China 10Department of Hematology, Lu'an Hospital Affiliated to Anhui MedicalUniversity, Lu'an, China 11Princess Margaret Cancer Centre, University Health Network, Toronto,Ontario, Canada
Correspondence Zimin Sun and Xiaoyu Zhu, Li Zhang
Baolin Tang, JongBok Lee, Siqi Cheng, and Tianzhong Pan contributed equally to this work.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used as a potentially curative treatment option for high-risk and refractory or relapsed acute myeloid leukemia (AML) patients.1 However, about 40% of allo-HSCT patients experiences disease relapse.1 Traditionally, allo-HSCT patients with recurrent disease may be treated with salvage therapies such as chemotherapy, donor lymphocyte infusion (DLI), or secondary allo-HSCT.1 However, disease relapse remains one of the main causes of death due to low response rate to the commonly used salvage therapies.1 Hence, safe and effective treatment options are urgently needed for allo-HSCT patients.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기